Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables Refunds (2016 - 2025)

Historic Receivables Refunds for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $2.1 million.

  • Amphastar Pharmaceuticals' Receivables Refunds fell 6139.47% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 6139.47%. This contributed to the annual value of $1.7 million for FY2024, which is 23212.93% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Receivables Refunds stood at $2.1 million, which was down 6139.47% from $1.6 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Receivables Refunds' 5-year high stood at $11.4 million during Q3 2022, with a 5-year trough of $126000.0 in Q4 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Receivables Refunds averaged around $1.9 million, with its median value being $784000.0 (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Receivables Refunds surged by 208557.69% in 2022 and then plummeted by 8674.88% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Receivables Refunds (Quarter) stood at $126000.0 in 2021, then soared by 35.71% to $171000.0 in 2022, then skyrocketed by 207.6% to $526000.0 in 2023, then skyrocketed by 232.13% to $1.7 million in 2024, then grew by 18.2% to $2.1 million in 2025.
  • Its Receivables Refunds stands at $2.1 million for Q3 2025, versus $1.6 million for Q2 2025 and $758000.0 for Q1 2025.